Abstract: Sulfonyl hydroxamic acid compounds have the following general formula: Ring A and B are aryl, heteroaryl, cycloalkyl, fused aryl or fused alkyl group, and R1, R2, R3, R4, R5, and R6 are hydrogen, alkoxy, aryloxy, hydroxy, ester, amide, amino, alkyl, aryl, heteroaryl, halogen, hydroxy, alkoxy, aryloxy, nitro, cyano, ester, or aldehyde. The compounds are HDAC inhibitors. Processes can be used for preparation of these indole-based sulfonyl hydroxamic acid derivatives.

Abstract: Sulfonyl hydroxamic acid compounds have the following general formula: Ring A and B are aryl, heteroaryl, cycloalkyl, fused aryl or fused alkyl group, and R1, R2, R3, R4, R5, and R6 are hydrogen, alkoxy, aryloxy, hydroxy, ester, amide, amino, alkyl, aryl, heteroaryl, halogen, hydroxy, alkoxy, aryloxy, nitro, cyano, ester, or aldehyde. The compounds are HDAC inhibitors. Processes can be used for preparation of these indole-based sulfonyl hydroxamic acid derivatives.

Abstract: The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) (as described herein) or pharmaceutically acceptable salts, solvates, stereoisomers or diastereoisomers thereof or pharmaceutical compositions containing the compounds of Formula (I) for use in the prevention and/or treatment of oral mucositis caused by cancer therapy such as radiation therapy.

Abstract: The present disclosure relates to an anti-acne formulation comprising at least one active ingredient selected from the group consisting of coumarin based compounds of Formula I and Formula II; or pharmaceutically acceptable salts, polymorphs and derivatives thereof, and at least one pharmaceutically acceptable excipient. The present disclosure also relates to its application for preventing/curing/treating various acne conditions.

Abstract: Call center personnel, i.e., company agents may be monitored and information from monitoring the call center agents may be presented on a portable device. The information from monitoring the call center agents may include various key performance indexes (KPIs) that enable the performance of the call center agents to be assessed. The KPIs may be updated in near-real time based on monitoring pending calls handled by the agents. Sound analytics may also be performed on the calls. Information regarding the call center agents may be graphically organized by the portable device so that call centers agents who may need assistance may be easily identified. The portable device may join a call. For example, a setting for a session associated with the call may be modified to include the manager device in the session.

Abstract: The present invention relates to a herbal composition comprising a therapeutically effective amount of an extract of the plant Terminalia elliptica as an active ingredient and optionally, a pharmaceutically acceptable carrier. The invention also relates to a process for the preparation of the extract. The invention also relates to a method for the treatment of metabolic disorders using the composition. The present invention also relates to a composition comprising a therapeutically effective amount of an extract of the plant Terminalia elliptica for use in combination with one or more further therapeutically active agent for the treatment of metabolic disorders.

Abstract: The present invention relates to a herbal composition for use in the prevention or treatment of a disease mediated by TNF-?. The present invention also provides a method for the preparation of the herbal composition and methods for using such herbal composition.

Abstract: A process for preparing an extract of Momordica charantia, including: a) preparing crude juice; b) filtering to obtain filtered juice; c) modifying pH; d) allowing the pH modified juice to stabilize; e) neutralizing the stabilized juice; f) allowing the neutralized juice to stand for 20-30 minutes; g) rechecking the pH level; and h) drying the juice to obtain the extract. The process said above is simple, cost effective, which does not employ any harmful organic solvents and which enhances the potency of the constituents. A simple and potent formulation showing anti-diabetic activity comprising active constituents of Momordica charantia is also provided.

Abstract: The present invention relates to an herbal composition comprising a therapeutically effective amount of the extract of a plant belonging to Calophyllum species as an active ingredient and optionally, a pharmaceutically acceptable carrier. The present invention also relates to herbal composition comprising extract obtained from the plant Calophyllum inophyllum. The invention also relates to a process for the preparation of the extract. The invention also relates to a method for the treatment of metabolic disorders using the said composition. The present invention also relates to a composition comprising a therapeutically effective amount of extract of the plants from Calophyllum species in combination with a known therapeutically active agent for use in the treatment of metabolic disorders.

Abstract: The present disclosure relates to an anti-acne formulation comprising at least one active ingredient selected from the group consisting of coumarin based compounds of Formula I and Formula II; or pharmaceutically acceptable salts, polymorphs and derivatives thereof, and at least one pharmaceutically acceptable excipient. The present disclosure also relates to its application for preventing/curing/treating various acne conditions.

Abstract: The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) or pharmaceutically acceptable salts, solvates, stereoisomers or diastereoisomers thereof or pharmaceutical compositions containing the compounds of Formula (I) for use in the prevention and/or treatment of oral mucositis caused by cancer therapy such as radiation therapy.

Abstract: The present invention relates to a combination for the treatment of cancer wherein the combination exhibits a synergistic effect. The combination comprises radiation and at least one cyclin dependent kinase (CDK) inhibitor selected from the compounds of formula I or a pharmaceutically acceptable salt or a solvate thereof. The present invention also relates to a method for the treatment of cancer, which method comprises administering to a patient in need of such a treatment, a therapeutically effective amount of the combination. The present invention also relates to the use of a CDK inhibitor selected from the compounds of formula I as a radiosensitizer that enhances the efficacy of radiotherapy for the treatment of cancer, particularly head and neck cancer.

Abstract: A novel pharmaceutical combination comprising a cytotoxic antineoplastic agent selected from a the group consisting of paclitaxel, docetaxel, doxorubicin and gemcitabine or a pharmaceutically acceptable salt thereof and at least one cyclin dependent kinase (CDK) inhibitor; wherein the said combination exhibits synergistic effects when used in the treatment of cancer. The invention also relates to a method for the treatment of cancer, using a therapeutically effective amount of the said combination.

Abstract: Embodiments of the present disclosure are directed to a system and method for receiving a request for TV programming schedule information via an interactive programming guide, obtaining the TV programming schedule information associated with a period of time, displaying one or more program icons having the TV programming schedule information associated with the interactive programming guide; adjusting at least one of a date toolbar for selecting one or more dates and a time toolbar for selecting one or more time periods of a day in response to receiving one or more commands; and displaying the one or more program icons having the TV programming schedule information associated with the interactive programming guide based at least on one of the selected one or more dates and the selected one or more time periods of the day.

Abstract: A process for preparing an extract of Momordica charantia, including: a) preparing crude juice; b) filtering to obtain filtered juice; c) modifying pH; d) allowing the pH modified juice to stabilize; e) neutralizing the stabilized juice; f) allowing the neutralized juice to stand for 20-30 minutes; g) rechecking the pH level; and h) drying the juice to obtain the extract. The process said above is simple, cost effective, which does not employ any harmful organic solvents and which enhances the potency of the constituents. A simple and potent formulation showing anti-diabetic activity comprising active constituents of Momordica charantia is also provided.

Abstract: The present invention provides the compounds of formula (I): The present invention relates to imidazo[4,5-c]quinoline derivatives of formula (I), process for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases mediated by phosphatidylinositol-3-kinase (PBK) and/or mammalian target of rapamycin (mTOR) and/or tumor necrosis factor-? (TNF-oc) and/or interleukin-6 (IL-6), particularly in the treatment of cancer and inflammation.

Abstract: A method, performed by a computer device, may include retrieving a document and determining context information associated with the document. The method may further include identifying an element in the document, where the element includes a context-dependent style specification; determining whether a context associated with the context-dependent style specification matches the determined context information; and applying a style associated with the context-dependent style specification to the element, when the context associated with the context-dependent style specification matches the determined context specification.

Abstract: This invention relates to a novel herbal composition comprising an extract of flowering and fruiting heads of the plant, Sphaeranthus indicus. The said extract of Sphaeranthus indicus contains a compound, 3a-hydroxy-5a,9-dimethyl-3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1,2-b]furan-2-one (7-Hydroxy-4,11(13)-eudesmadien-12,6-olide) (compound 1), as a bioactive marker. The invention also relates to a composition comprising 3a-hydroxy-5a,9-dimethyl-3-methylene-3a,4,5,5a,6,7,8,9b-octahydro-3H-naphtho[1,2-b]furan-2-one (compound 1) as an active ingredient. The invention also relates to methods of manufacture of the said compositions. The invention also relates to methods of administration of the said compositions to a subject in need of treatment for an inflammatory disorder. The invention also relates to tumor necrosis factor- (TNF-?) and interleukin (IL-1, IL-6, IL-8) inhibitory activity of the said compositions.

Abstract: The present invention provides the compounds of formula (I): The present invention relates to imidazo[4,5-c]quinoline derivatives of formula (I), process for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases mediated by phosphatidylinositol-3-kinase (PBK) and/or mammalian target of rapamycin (mTOR) and/or tumor necrosis factor-? (TNF-oc) and/or interleukin-6 (IL-6), particularly in the treatment of cancer and inflammation.

Abstract: Compounds of formula 1: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-?) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-? activity, in particular inflammations.